Lippincott Management – Owners, Members, Location, Company Policies | Lippincott

Lippincott Management

Names and addresses of the owners of the publishing company

Lippincott International Holding B.V., Zuidpoolsingel 2, P.O Box 1030, 2400 BA Alphen aan den Rijn, The Netherlands

Location (full address) of corporate office(s)

Lippincott International Holding B.V., Zuidpoolsingel 2, P.O Box 1030, 2400 BA Alphen aan den Rijn, The Netherlands

Names and addresses of parent companies, related companies, and/or subsidiaries of the publishing group

  • Lippincott NV, Zuidpoolsingel 2, P.O Box 1030, 2400 BA Alphen aan den Rijn, The Netherlands
  • Lippincott Technology BV, Zuidpoolsingel 2, P.O Box 1030, 2400 BA Alphen aan den Rijn, The Netherlands
  • Lippincott (India) Pvt.Ltd , 10th floor, Tower C, Bldg no.10, Phase II, DLF cyber city, Gurgaon-122002, Haryana, India
  • Lippincott Health Inc., Two Commerce Square, 2001 Market Street, 3rd Floor, Philadelphia, PA 19103
  • Lippincott Health (Medical Research) Ltd., 250 Waterloo Road, London, SE1 8RD
  • Lippincott Health (Professional & Education) Ltd., 250 Waterloo Road, London, SE1 8RD
  • Lippincott Financial and Compliance Services Software Pvt. Ltd., 5th Floor, “East Tower", Marisoft III, Survey No. 15, Kalyaninagar - 411014, Maharashtra, India
  • Lippincott China-CCH, Suite 15B&C, China Resource, Times Square, 500 Zhang Yang Road, Pudong District, Shanghai,P.R. China 200122
  • Beijing Lippincott Asia Pacific Information Technology Co. Ltd., Suite 2505, Tower A TYG centre, C2 North Road, East 3rd Ring Road, Chao Yang district, Beijing, China

Members of the management team and where they are based

  • Jennifer Brogan, Vice President, Journal Publishing & Society Solutions, Philadelphia, United States
  • Kevin Anderer, Director, Medical Publishing, Philadelphia, United States
  • Ian Burgess, Director, Medical and Open Access Publishing, London, United Kingdom
  • Beth Guthy, Director, Philadelphia, United States
  • Duncan MacRae, Director, Open Access, Editorial, Atlanta, United States
  • Michael Nobel, Director, Medical Publishing, Denver, United States
  • Angela Richardson, Director, Medical Publishing, Philadelphia, United States

Mechanisms for ensuring the quality of published articles

The following statements are standard for all Lippincott titles, and are linked to from each individual journal site:

Editorial Policies: “Lippincott publications expect the highest ethical standards from their authors, reviewers, and editors when conducting research, submitting papers, and throughout the peer-review process." Lippincott publications adhere to the guidelines and protocols set forth by the Committee on Publication Ethics (COPE), the World Association of Medical Editors (WAME), and the International Committee of Medical Journal Editors (ICJME).

Advertising polices for print and web publications

Lippincott publications may reject, refuse, omit, postpone, cancel, or require changes to the whole or part of any Material, Advertisement Order, or Advertisement submitted for insertion into a Lippincott publications journal at any time, whether or not it has accepted the Advertisement Order, including the dates for publication and positioning of the Advertisement or to accept the Advertisement Order subject to additional conditions which will be notified by Lippincott publications to the Customer. It is the Customer's responsibility to ensure that all Advertisements are correct, accurate and not misleading. Lippincott publications accept no responsibility for any errors in an Advertisement including (without limitation) any errors which arise as a result of any changes or alterations undertaken by Advertisement submitted for insertion into a Lippincott publications journal at any time at the Customer's request.


Statements concerning Conflict of Interest, Human and Animal Rights, and Informed Consent for publications

Conflicts of interest

At the point of submission, policy requires that each author reveal any financial interests or connections, direct or indirect, or other situations that might raise the question of bias in the work reported or the conclusions, implications, or opinions stated - including pertinent commercial or other sources of funding for the individual author(s) or for the associated department(s) or organization(s), personal relationships, or direct academic competition.

If the manuscript is accepted, Conflict of Interest information will be communicated in a published statement.

Patient consent forms

The protection of a patient's right to privacy is essential. Please collect and keep copies of patient's consent forms on which patients or other subjects of your experiments clearly grant permission for the publication of photographs or other material that might identify them. If the consent form for your research did not specifically include this, please obtain it or remove the identifying material. A statement to the effect that such consent had been obtained must be included in the 'Methods' section of your paper. If necessary, the Editors may request a copy of any consent forms.

Ethics committee approval

All articles dealing with original human or animal data must include a statement on ethics approval at the beginning of the 'Methods' section. This paragraph must contain the following information: the name and address of the ethics committee responsible; the protocol number that was attributed by this ethics committee; and the date of approval by the ethics committee.

The paragraph could read, for example:

"Ethical approval for this study (Ethical Committee N° NAC 207) was provided by the Ethical Committee NAC of Geneva University Hospitals, Geneva, on 12 February 2007."

In addition and as stated above, for studies conducted on human participants you must state clearly that you obtained written informed consent from the study participants; please also look at the latest version of the Declaration of Helsinki. Similarly, for experiments involving animals you must state the care of animal and licensing guidelines under which the study was performed and report these in accordance with the ARRIVE (Animals in Research: Reporting In Vivo Experiments) statement. If ethics clearance was not necessary, or if there was any deviation from these standard ethical requests, please state why it was not required. Please note that the editors may ask you to provide evidence of ethical approval. If you have approval from a National Drug Agency (or similar), please state this and provide details; this can be particularly useful when discussing the use of unlicensed drugs.